Skip Nav Destination
1-15 of 15
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Krish Patel, Peter A. Riedell, Hervé Tilly, Sairah Ahmed, Jean-Marie Michot, Herve Ghesquieres, Jean Marc Schiano de Collela, Asher Chanan-Khan, Kamal Bouabdallah, Benoit Tessoulin, Sunil Iyengar, Meixiao Long, Raphael Clynes, Jitendra Kanodia, Lei Bao, Ying Ding, Jianhua Jin, William B Ainsworth, Raman Garcha, Steve Kye, Tycel J. Phillips
Blood (2022) 140 (Supplement 1): 9470–9472.
The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)
Alexander Marr, Soumendrakrishna Karmahapatra, Dominique Corbin, Yerdanos Asemelash, Steven Sher, Shaneice Renee Mitchell, Bonnie K Harrington, Shelley Orwick, Larry Beaver, Ronni Wasmuth, Virginia Goettl, Alice S. Mims, Karilyn T. Larkin, Sumithira Vasu, Meixiao Long, James S. Blachly, Ramiro Garzon, John C. Byrd, Rosa Lapalombella, Nicole Grieselhuber
Blood (2022) 140 (Supplement 1): 3075–3076.
Kieran D Sahasrabudhe, Melanie T Rebechi, Ying Huang, Greg K. Behbehani, Bhavana Bhatnagar, James S. Blachly, Bradley W Blaser, Uma Borate, Ramiro Garzon, Tamanna Haque, Karilyn Larkin, Meixiao Long, Alice S. Mims, Ayman Saad, Sumithira Vasu, Alison R. Walker, Sarah A Wall
Blood (2021) 138 (Supplement 1): 4125.
Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Javier Pinilla Ibarz, Meixiao Long, John Lister, Jennifer A. Woyach, Friedrich Graf Finckenstein, Madan Jagasia, Selda Samakoglu, Bhagyashree Yadav, Huiling Li, John C. Byrd
Blood (2021) 138 (Supplement 1): 3846.
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD
Blood (2019) 134 (Supplement_1): 834.
Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD
Blood (2019) 134 (Supplement_1): 1049.
Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation
Caner Saygin, MD, John L Vaughn, MD, Joseph Coleman, Marcin Puto, PharmD, Julianna Roddy, PharmD, Sam Penza, MD, Jonathan E. Brammer, MD, Yvonne Efebera, MD, Don M. Benson, Jr., MD PhD, Sumithira Vasu, MD MBBS, Alison R. Walker, MD, Alice S. Mims, MD, Bhavana Bhatnagar, DO, Bradley Wayne Blaser, MD, Maria Chaudhry, MD, Hannah K. Choe, MD, Karilyn Larkin, MD, Meixiao Long, MD, Ashley E. Rosko, MD, Nicole Grieselhuber, MD PhD, Sarah A Wall, MD, Steven Devine, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD
Blood (2018) 132 (Supplement 1): 3357.
Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia
Lavakumar Karyampudi, PhD, Ian Frank, Michelle Blaskovich, John C. Byrd, MD, Cecile Chartier, Meixiao Long, MD
Blood (2018) 132 (Supplement 1): 5683.
Blood (2018) 132 (21): 2212–2213.
Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients
Nyla A. Heerema, PhD, Qiuhong Zhao, MS, Amy S. Ruppert, MAS, Heather Breidenbach, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Jennifer A. Woyach, MD, Farrukh T. Awan, Meixiao Long, MD PhD, Amber Gordon, MLS, Caitlin Coombes, BA, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD
Blood (2016) 128 (22): 4372.
BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia
Yo-Ting Tsai, MS, Aparna Lakshmanan, PhD, Amy M. Lehman, MAS, Ellen J. Sass, Minh Tran, Fabienne McClanahan, MD PhD, Meixiao Long, MD PhD, Bonnie K. Harrington, DVM, Krista La Perle, DVM, PhD, Vincenzo Coppola, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Michael R. Grever, MD, David M. Lucas, PhD
Blood (2016) 128 (22): 1206.
Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism
Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Blood (2016) 128 (22): 3238.
Clinical Trials & Observations
Joseph A. Fraietta, Kyle A. Beckwith, Prachi R. Patel, Marco Ruella, Zhaohui Zheng, David M. Barrett, Simon F. Lacey, Jan Joseph Melenhorst, Shannon E. McGettigan, Danielle R. Cook, Changfeng Zhang, Jun Xu, Priscilla Do, Jessica Hulitt, Sagar B. Kudchodkar, Alexandria P. Cogdill, Saar Gill, David L. Porter, Jennifer A. Woyach, Meixiao Long, Amy J. Johnson, Kami Maddocks, Natarajan Muthusamy, Bruce L. Levine, Carl H. June, John C. Byrd, Marcela V. Maus
Blood (2016) 127 (9): 1117–1127.
Includes: Supplemental data
Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients
Meixiao Long, MD PhD, Kyle A. Beckwith, BS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Blood (2015) 126 (23): 2940.
T-bet Down-Modulation in Tolerized Th1 Effector CD4 Cells Confers a TCR-Distal Signaling Defect That Selectively Impairs IFN- γ Expression.
Meixiao Long, Aaron M. Slaiby, Adam T. Hagymasi, Marianne A. Mihalyo, Alexander C. Lichtler, Steven L. Reiner, Adam J. Adler
Blood (2005) 106 (11): 3321.